Sana Biotechnology (SANA) Q3 2026 earnings review
Sana's diabetes cells still work, but cash lasts until mid-2027
Sana Biotechnology, which develops engineered cell therapies, reported an accounting profit while spending more cash on research. The profit came from cutting the estimated value of payments it may owe the sellers of a gene-delivery business it bought. Excluding that gain, the loss widened to $43 million. Sana still expects its $122 million of cash to last into mid-2027.
| Quarterly loss, excluding one-off gains | $43.0M $39.0M a year ago |
|---|---|
| Cash used in operations, by our math | $34.1M +17.5% from a year ago |
| Research spending | $33.9M +12.7% from a year ago |
| Outlook for how long cash lasts | Unchanged into mid-2027 |
⚖️ Verdict: 🔴 Bearish
The story got worse because Sana moved the first data from SG293, its experimental lymphoma treatment, to next year, while its cash kept falling. Mayo Clinic also declined to buy another $25 million of shares. The good news: donor cells that make insulin still work in a Swedish patient after 14 months.
The question now is how Sana pays for its trials once its cash runs out around mid-2027. It can sell new shares or license its gene-delivery technology to a partner. The next financing and the first SG293 results, due in the first half of 2027, will tell.
🐂 Bull Case
Transplanted Cells Still Make Insulin After 14 Months
Sana's diabetes program depends on HIP, gene edits meant to hide donor cells from the immune system, so patients would need no immune-suppressing drugs. In a study at Uppsala University Hospital, one patient received UP421: donor islet cells, the pancreas cells that make insulin, with those edits.
Fourteen months after the transplant, the cells still release C-peptide, a marker of insulin production, at levels comparable to the first six months. Sana said the cells "have evaded immune detection" and reported no safety issues. Scans at weeks 12 and 52 found them at the transplant site in the forearm.
This matters because SC451, Sana's own version grown from stem cells so Sana can produce it at scale, uses the same edits. Chief executive Steve Harr said SC451 "may provide a rapid signal" on whether the cells hide and work. But UP421 has treated one patient, with donor cells rather than lab-grown ones.
What to watch: whether Sana files its application to begin human testing of SC451, which it plans "as early as this year". A filing and a first patient by December would keep first SC451 data possible in 2027, as Harr aims.
New Cobalt Terms Tie Payouts to Deals
Sana owes the former owners of Cobalt, a gene-delivery business it bought in 2019, up to $500 million if its programs reach set milestones. In August both sides rewrote the deal, and the new terms "reduce or defer the payment of certain milestone amounts until a change of control", meaning a sale of Sana.
Payments can now also come due when the cell-therapy developer collects money from partner deals. Sana said the rewrite was the main reason the obligation's estimated value fell $55.5 million. That helps, because more of the bill arrives only when cash comes in. But Sana still lists $40.6 million, a third of its cash, as owed within a year.
What to watch: whether any short-term amount comes due next quarter, and whether Sana pays in shares or cash. Paying cash would shorten the time its money lasts.
🐻 Bear Case
Cash Lasts About Three More Quarters
Sana sells no products, so investors fund its research. Its quarterly filing warns that its money "may not be sufficient to fund its planned operations for at least one year", which raises "substantial doubt" about whether it can keep operating.
By our math, the Seattle company used $34.1 million on operations in the third quarter, 17.5% above a year earlier. Mayo Clinic, its partner on SC451, let its option to buy another $25 million of shares lapse in August.
- Cash and investments: $121.7 million, down from $160.5 million in June
- Quarters of cash left at the third-quarter pace: about 3.6, by our math
- Money raised from share sales in 2026: $93.3 million, all in the second quarter
This matters because both lead programs enter human trials within months, and Sana names trials as the main driver of future cost increases. It also wrote that it will "need to raise additional capital within the next 12 months".
What to watch: the size of the next financing against the roughly $34 million Sana now uses each quarter. A raise below four quarters of spending would leave the warning about its future in place.
First Lymphoma Data Moves Into 2027
SG293, Sana's experimental lymphoma treatment, delivers genes that turn a patient's immune cells into cancer-killing CAR T cells inside the body. "We continue to make meaningful progress toward initiating clinical studies of SC451 later this year and SG293 in 1Q 2027," chief executive Steve Harr said.
The release calls this "Continued progress toward starting clinical study for SG293". Yet three months ago, Sana pointed to first data as early as this year. Now data come as early as the first half of 2027. The delay also holds back SG227, its myeloma treatment, which starts "contingent upon the early clinical profile of SG293".
What to watch: whether Sana doses the first SG293 patient in the first quarter of 2027. Another delay would push first data beyond mid-2027, the limit of Sana's current cash.
Excluding an Accounting Gain, the Loss Widened
Sana reported net income of $20.4 million, against a $42.2 million loss a year ago. A $63.4 million non-cash gain on payments it may owe Cobalt's former owners and Harvard produced that profit.
Excluding those gains, the loss widened 10% to $43.0 million. Research spending rose 12.7%, because contract manufacturing for SC451 and SG293 cost more and SC451 lab work expanded. The rise is recent: over nine months, research spending still fell 3.8%, because Sana employed fewer researchers after suspending two older programs.
What to watch: fourth-quarter research spending, which the 2026 plan keeps near last year's $34.9 million, by our math. A much higher figure would mean trial costs are arriving before new money does.
👓 Other Themes
Sana Hands Back Part of Its California Lab Space
In the third quarter Sana amended its South San Francisco lease, ending it for part of the space from April 30, 2027. It paid a termination fee of about $3.8 million, which it leaves out of its own cash-burn measure. The change cut the future rent it records as owed by about $12.0 million.
💲 Other KPIs
Sana's share count kept climbing as it sold stock to pay for research: the quarter's average was 17.9% above a year ago. Growth eased from 24.0% in the second quarter, because Sana sold no new shares in the third. Each holder now owns a smaller part of the company.
Spending on equipment reached $2.7 million in nine months, against $0.1 million a year ago, mostly for laboratory equipment. The amount remains small next to quarterly cash use, because Sana stopped building its own plant in Bothell, Washington, in 2025 and relies on contract manufacturers.
Pay in shares and options, a cost that uses no cash, dipped 2.8% from a year ago to $5.3 million. It has stayed near that level all year, so it adds steadily to the share count over time.
🔮 Guidance
Unchanged. Sana still expects its money to last into mid-2027. By our math, $121.7 million covers about 3.6 quarters at the third quarter's pace. The date moved later twice this year, each time after Sana sold shares, while it warns that it must raise more within 12 months.
New. Sana plans research spending this year "materially flat or slightly lower" than in 2025. By our math, taking a 5% cut as the low end, the middle of that range leaves about $35 million for the fourth quarter, about 1% above a year ago. That would slow a climb that reached 12.7% in the third quarter.
New. Sana expects overhead, its general and administrative costs, to match 2025. By our math, that leaves about $11.1 million for the fourth quarter, down about 9% from a year ago, after two quarters of increases. Sana blamed this year's rise on higher facility costs.
Unchanged. Sana still plans to file its application to begin human testing of SC451, its diabetes cell therapy, and start the first trial this year. Less than two months remained when it released results. The diabetes developer has given the same 2026 timing for a year.
Cut. Sana now plans to start the SG293 lymphoma trial in the first quarter of 2027, with first data as early as the first half. Three months ago it pointed to data as early as this year. A year ago it aimed only to file the application in 2027, so the earlier plan did not hold.
Unchanged in substance. Sana still ties its myeloma program's start to how SG293 performs in its first patients, and now says "as early as 2027" instead of mid-2027. Because SG293 data moved into the first half of 2027, the SG227 decision rests on a later reading than before.
❓ Key Questions
How will Sana fund its work beyond mid-2027?
Sana says it must raise money within 12 months, and the Mayo Clinic option lapsed. Investors need the plan: a share sale, a partnership on its gene-delivery technology, or both, and roughly how much each could bring.
What moved SG293's first patient data into 2027?
Three months ago Sana pointed to data as early as 2026. The cause, whether manufacturing, regulators or trial sites, decides whether the first-quarter start date holds.
Has Sana filed the SC451 application with US regulators?
The release repeats 'as early as this year' with weeks left. A filing date and first-patient timing would show whether the diabetes trial can produce data in 2027, as chief executive Steve Harr aims.
What could trigger the $40.6 million short-term Cobalt payment?
Sana lists this part of the Cobalt obligation as owed within a year. Which milestone triggers it, and whether Sana would pay in shares or cash, decides how long its money lasts.
Why did Mayo Clinic decline to buy more shares?
Mayo Clinic let its option to invest another $25 million lapse in August, while the SC451 collaboration continues. Sana has not said whether the partnership's scope or terms changed.